ERBB2 and bone metastasis: If patients had none of the brain, liver, and lung metastases, the number of bone metastasis in both TNBC (191/6350, 3%) and HER2 (50/1959, 2.6%) patients was lower than that in luminal A (999/27734, 3.6%) and B (164/4074, 4%) subtypes (p = 0.003).